MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Acquires New Stake in Zoetis Inc. $ZTS

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new position in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 13,302 shares of the company’s stock, valued at approximately $2,074,000.

Other large investors have also recently modified their holdings of the company. Nova Wealth Management Inc. purchased a new stake in Zoetis in the first quarter valued at approximately $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis during the 1st quarter valued at $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter worth $29,000. Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after purchasing an additional 120 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.5%

Shares of Zoetis stock opened at $141.03 on Friday. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $197.51. The company’s fifty day simple moving average is $150.45 and its 200-day simple moving average is $155.86. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a market capitalization of $62.50 billion, a PE ratio of 24.27, a P/E/G ratio of 2.27 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on ZTS shares. Argus reissued a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.